 |
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
|
Hanke
to head BioVex commercialization
BioVex Inc., a Woburn-based developer of cancer and infectious disease drugs and vaccines, has named Tim Hanke as its vice president of commercial operations. He will be responsible for moving the company’s OncoVEX GM-CSF product to commercialization.
Hanke joins BioVex having previously served as director of global commercial operations at Genta Inc., a biopharmaceutical firm also dedicated to cancer treatment. Prior to Genta, he worked for Chiron Biopharmaceuticals and Berlex Laboratories Inc.
OncoVEX GM-CSF is a cancer treatment, which BioVex calls an “oncolytic vaccine,” made to destroy cancer cells without harming healthy cells. The treatment is currently in a Special Protocol Assessment (SPA) Phase 3 study for melanoma, and the FDA has approved it for a Phase 3 study for head and neck cancer, also under SPA.
More about BioVex
In November, BioVex capped its Series F round of funding with $30 million
to add to its first $40 million of the round announced in March. The new
funding saw participation from new investors including Sectoral Asset
Management and Ysios Capital Partners, and the round was co-led by Morningside
Venture, Ventech and MVM Life Science Partners.
BioVex has its headquarters in Woburn and maintains its research and development facility in Oxford, England.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|